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Abstract 
Artichoke (A), borututu (B) and milk thistle (M) are included in several supplements to 
provide beneficial effects. Different formulations (infusions, pills and syrups), as also 
different proportions of A, B and M (1:1:1, 2:1:1, 1:2:1, 1:1:2) within each formulation 
were assayed to optimize the desired benefits. The antioxidant activity, anti-
hepatocellular carcinoma activity, hepatotoxicity and bioactive compounds contents 
were evaluated. Syrups tended to be the formulation with highest antioxidant activity 
and total phenolics and flavonoids content; otherwise, pills were the worst formulation. 
In what concerns A:B:M ratios, the results did not reveal so pronounced differences. 
None of the assayed mixtures resulted to be toxic (up to the maximum assayed dose) for 
liver primary cells (PLP2), but some samples, especially infusions, showed toxicity for 
the hepatocellular carcinoma cell line (HepG2). With no exception, the mixtures for all 
formulations gave synergistic effects in antioxidant activity, when compared to the 
activity of single plants.  
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Introduction  
Artichoke (Cynara scolymus L.), borututu (Cochlospermum angolensis Welw.) and 
milk thistle (Silybum marianum (L.) Gaertn) are medicinal plants with numerous 
pharmacological effects, such as antioxidant and hepatoprotective activities, as 
described in different studies;1-3 borututu is also recognized as an antimalarial herb,4 
while milk thistle prevent spleen and gallbladder disorders,5 and artichoke leaves are 
used for the treatment of dyspepsia and diabetes.6  
Phytochemicals are very prone to variations depending on the plant material (that 
changes within phenological cycle), harvest, drying and storage conditions.7 The 
genetic, cultural and environmental factors that explain this variability make their use 
rather challenging and frequently problematic because the active principles are diverse 
and may be unknown.7,8 In some cases, these effects might even be harmful; for 
instance, the leaf extracts of artichoke caused chromosomal instability and cytotoxicity 
in hamster ovary cells,9 while milk thistle extracts, at 15 µg/mL, showed toxicity against 
the activity of hepatic P450 cytochrome.10  
The consumption of supplements to provide the beneficial effects of certain plants has 
raised several controversial questions, such as those pointed out by Halliwell, who 
stated that “we cannot just pull out one or two individual molecules and expect pills 
containing high doses of them to protect us”,11 suggesting the whole herbal medicine as 
one active ingredient, i.e., a set of multi-component parts self-organized into an 
indivisible whole.12 Nonetheless, there is an increasing number of formulations based 
on these plants due to their therapeutic applications, namely infusions, pills, capsules, 
ampoules, syrups, among others.  
The bioactivity of the most consumed forms (infusions, pills, and syrups) of borututu, 
milk thistle, and artichoke was assessed by our research group and these formulations 
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revealed not only antioxidant and hepatoprotective effects, but also synergism between 
the three plants in syrups.13,14 Thus, given the importance of the studied plants in the 
treatment of liver diseases and the availability of so many formulations, it seems very 
pertinent to find the better way to achieve the desired benefits from these herbs 
depending on the kind of formulation, the plant present on it, or even the percentage of 
each plant in formulations containing the three mentioned plants. To deepen that 
question, in the present work we investigated the antioxidant and anti-hepatocellular 
carcinoma activities of twelve mixtures with four different proportions of artichoke, 
borututu and milk thistle, and different formulations of each plant (infusions, pills and 
syrups). 
 
Experimental 
Samples and samples preparation 
Cynara scolymus L. (artichoke; A), Cochlospermum angolensis Welw. (borututu; B) 
and Silybum marianum (L.) Gaertn (milk thistle; M) were obtained from an herbalist 
shop in Bragança (Portugal), as dry material for infusions (leaves, plant and bark, 
respectively), pills (based-on plant and roots, in the case of B), and syrups (containing 
100% of A, 10% of B roots, and 2.3% of M). Each sample was used as recommended in 
the label: the infusions were prepared from the dry material and further lyophilized, the 
pills were powdered and the syrups were directly used. 
Each formulation (infusion, pill and syrup) of A, B and M, respectively, was mixed in 
different proportions: 1:1:1; 2:1:1; 1:2:1; and 1:1:2 (m/m/m), and further dissolved in 
distilled water to a final concentration of 6 mg/mL. The twelve stock solutions (four 
mixtures of infusions, four mixtures of pills and four mixtures of syrups) were 
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successively diluted and submitted to an evaluation of antioxidant activity, anti-
hepatocellular carcinoma activity and hepatotoxicity.  
 
Standards and reagents 
2,2-Diphenyl-1-picrylhydrazyl (DPPH) was obtained from Alfa Aesar (Ward Hill, MA, 
USA). Gallic acid, catechin, trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid), ellipticine, phosphate buffered saline (PBS), acetic acid, 
sulforhodamine B (SRB), trichloroacetic acid (TCA) and Tris were purchased from 
Sigma (St. Louis, MO, USA). Foetal bovine serum (FBS), L-glutamine, Hank’s 
balanced salt solution (HBSS), trypsin-EDTA (ethylenediaminetetraacetic acid), 
nonessential amino acids solution (2 mM), penicillin/streptomycin solution (100 U/mL 
and 100 mg/mL, respectively) and DMEM (Dulbecco's Modified Eagle Medium) were 
from Hyclone (Logan, UT, USA). Water was treated in a Milli-Q water purification 
system (TGI Pure Water Systems, Greenville, SC, USA).  
 
Antioxidant activity 
DPPH radical-scavenging activity was evaluated by using an ELX800 microplate reader 
(Bio-Tek Instruments, Inc; Winooski, VT, USA), and calculated as a percentage of 
DPPH discolouration using the formula: [(ADPPH-AS)/ADPPH] × 100, where AS is the 
absorbance of the solution containing the sample at 515 nm, and ADPPH is the 
absorbance of the DPPH solution. Reducing power was evaluated by the capacity to 
convert Fe3+ into Fe2+, measuring the absorbance at 690 nm in the microplate reader 
mentioned above. Inhibition of β-carotene bleaching was evaluated though the β-
carotene/linoleate assay; the neutralization of linoleate free radicals avoids β-carotene 
bleaching, which is measured by the formula: β-carotene absorbance after 2h of 
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assay/initial absorbance) × 100. Lipid peroxidation inhibition in porcine (Sus scrofa) 
brain homogenates was evaluated by the decreasing in thiobarbituric acid reactive 
substances (TBARS); the colour intensity of the malondialdehyde-thiobarbituric acid 
(MDA-TBA) was measured by its absorbance at 532 nm; the inhibition ratio (%) was 
calculated using the following formula: [(A - B)/A] × 100%, where A and B were the 
absorbance of the control and the sample solution, respectively.15 The results were 
expressed in EC50 values (sample concentration providing 50% of antioxidant activity 
or 0.5 of absorbance in the reducing power assay). Trolox was used as positive control. 
 
Bioactive compounds content 
Total phenolics were estimated by Folin-Ciocalteu colorimetric assay according to 
procedures previously described16 and the results were expressed as mg of gallic acid 
equivalents (GAE) per g of extract. 
Total flavonoids were determined by a colorimetric assay using aluminum trichloride, 
following procedures previously reported;16 the results were expressed as mg of (+)-
catechin equivalents (CE) per g of extract. 
 
Anti-hepatocellular carcinoma activity and hepatotoxicity  
The anti-hepatocellular carcinoma activity was evaluated using HepG2, which is the 
most widely used tumor cell line and generally regarded as a good hepatocellular 
carcinoma model. HepG2 cells were routinely maintained as adherent cell cultures in 
DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin and 100 
mg/mL streptomycin, at 37 ºC, in a humidified air incubator containing 5% CO2. The 
cell line was plated at 1.0 × 104 cells/well in 96-well plates. Sulforhodamine B assay 
was performed according to a procedure previously described by the authors.17 
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For hepatotoxicity evaluation, a cell culture was prepared from a porcine liver obtained 
from a local slaughter house, according to a procedure established by the authors;17 it 
was designed as PLP2. Cultivation of the cells was continued with direct monitoring 
every two to three days using a phase contrast microscope. Before confluence was 
reached, cells were subcultured and plated in 96-well plates at a density of 1.0×104 
cells/well, and commercial in DMEM medium with 10% FBS, 100 U/mL penicillin and 
100 µg/mL streptomycin. The results were expressed in GI50 values (sample 
concentration that inhibited 50% of the net cell growth). Ellipticine was used as positive 
control.  
 
Classification of additive, synergistic or antagonistic effects  
Theoretical values for antioxidant and anti-hepatocellular carcinoma activities of the 
mixtures were calculated as weighted mean experimental EC50 or GI50 values of the 
individual samples14 and considering additive contributions of individual species in each 
percentage; for instance, mixture 2:1:1: EC50 = EC50A×0.5 + EC50B×0.25 + 
EC50M×0.25.  
The classification in additive (AD), synergistic (SN) or antagonistic (negative 
synergistic; AN) effects was performed as follow: AD: theoretical and experimental 
values reveal differences lower than 5%; SN: experimental values are more than 5% 
lower than theoretical values; AN: experimental values are more than 5% higher than 
theoretical values. For each case, the percentage was calculated as follows: 
[(experimental value – theoretical value)/experimental value]*100. 
 
Statistical analysis 
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All statistical tests were performed at a 5% significance level, using SPSS (v.20) 
software. For each formulation (F) and A:B:M ratio (R), three samples were analyzed, 
with all the assays being also carried out in triplicate. The results are expressed as mean 
value±standard deviation (SD). 
An analysis of variance (ANOVA) with type III sums of squares was performed using 
the GLM (General Linear Model) procedure of the SPSS software. The dependent 
variables were analyzed using 2-way ANOVA, with the factors F and R. In this case, 
when a statistically significant interaction (F×R) is detected, the two factors should be 
evaluated simultaneously by the estimated marginal means plots for all levels of each 
single factor. Alternatively, if no statistical significant interaction is verified, means 
might be compared using, for instance, Tukey’s honestly significant difference (HSD) 
multiple comparison test. 
Furthermore, a linear discriminant analysis (LDA) was used to compare the effect of F 
and R on antioxidant activity and extracted bioactive compounds. A stepwise technique, 
using the Wilks’ λ method with the usual probabilities of F (3.84 to enter and 2.71 to 
remove), was applied for variable selection. This procedure uses a combination of 
forward selection and backward elimination processes, where the inclusion of a new 
variable is preceded by ensuring that all variables selected previously remain 
significant.18,19 With this approach, it is possible to identify the significant variables 
obtained for each sample. To verify the significance of canonical discriminant 
functions, the Wilks’ λ test was applied. A leaving-one-out cross-validation procedure 
was carried out to assess the model performance.  
 
Results and Discussion 
 9 
Antioxidant properties and cytotoxicity for hepatocellular tumor cell line and liver 
primary cells 
There has been an intensive scientific effort to validate the effectiveness of herbal 
formulations, since the preparation of dietary supplements/nutraceuticals and some 
pharmaceutical products are based on the extraction of bioactive compounds from 
natural products.20 This scientific validation is often supported by evaluating the 
antioxidant activity of plant derived products, as a preliminary approach. Herein, four 
different assays were used: DPPH scavenging activity, reducing power (assessed by 
Ferricyanide/Prussian blue assay), β-carotene bleaching inhibition and TBARS 
formation inhibition. In addition, total phenolics and total flavonoids were also 
determined, bearing in mind that the antioxidant activity is often correlated with the 
contents in phenolic compounds.21 Also, HepG2 human cell line was used to assess 
anti-hepatocellular carcinoma activity, while a primary culture of porcine liver cells was 
established to evaluate hepatotoxicity. In fact, since some potential effects of 
compounds naturally present in plants are difficult to anticipate, the assessment of the 
safety of a plant extract used as a food or a medicine by the population is completely 
mandatory.9  
Three plant species, namely artichoke (A), borututu (B) and milk thistle (M), which are 
commonly present in nutraceutical formulations/dietary supplements, were selected due 
to their availability in different formulations. Besides aiming studying the influence of 
the formulation type in the bioactivity and phenolic compounds content, this study was 
designed also to evaluate supposed differences resulting from using different 
percentages of the plant species in each formulation.   
The effects of formulation type (F) and A:B:M ratio (R) were evaluated by fixing one of 
the factors; i.e., the results are presented as the mean of each F, comprising values for 
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all R in those conditions, as well as the mean of each R, containing the results for all the 
corresponding F. Accordingly, the standard deviation values should not be looked up as 
a simple measure of assays repeatability, since they reflect results from assays 
performed in different conditions.  
As it can be seen in Table 1, each factor showed a significant effect per se, but the 
interaction among factors (F×R) was also a significant (p<0.001) source of variation for 
all parameters, indicating a strong interaction between the formulation and the 
percentages of each plant in the prepared mixtures. Therefore, although the least squares 
means are presented, the results for multiple comparisons became meaningless. 
Nevertheless, from the analysis of the plots of the estimated margins means (Figures 1 
and 2), some particular tendencies can be observed. For instance, pill formulation gave 
lower antioxidant activity in all antioxidant assays (DPPH scavenging activity: EC50 = 
1.2 mg/mL; reducing power: EC50 = 0.4 mg/mL; β-carotene bleaching inhibition: EC50 
= 2 mg/mL; TBARS formation inhibition: EC50 = 0.3 mg/mL) and also lower contents 
in total phenolics (69 mg GAE/g) and total flavonoids (5 mg CE/g) contents; syrups and 
infusions presented similar antioxidant activity levels, except for reducing power (lower 
on infusion), but total phenolics (469 mg GAE/g) and total flavonoids (78 mg CE/g) 
contents were higher in syrups. In what concerns A:B:M ratios, the results did not 
reveal so pronounced differences, except for the lower DPPH scavenging activity (EC50 
= 1.0 mg/mL), β-carotene bleaching inhibition (EC50 = 2 mg/mL) and TBARS 
formation inhibition (EC50 = 0.2 mg/mL) in mixtures 2:1:1, 1:1:2 and 1:1:1, 
respectively. 
Besides the pointed out differences, the assayed mixtures and formulations proved to 
have higher antioxidant activity than previously assayed formulations, namely syrups 
with a A:B:M ratio of 1:1:2.35, except in the case of β-carotene bleaching inhibition, to 
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which the results were similar.14 A similar result was obtained for the anti-
hepatocellular carcinoma activity, which demonstrated to be higher in the present report 
when compared to the results obtained from infusion, pills or syrups based on a single 
species or in mixtures different than those assayed herein. This antitumor activity was 
especially high in infusions (1:1:1, GI50 = 24 µg/mL; 2:1:1, GI50 = 49 µg/mL; 1:2:1, 
GI50 = 63 µg/mL; 1:1:2, GI50 = 67 µg/mL). None of the samples showed hepatotoxicity 
(GI50 > 400 µg/mL, in all cases), which represents an important result considering the 
need of obtaining innocuous formulations. 
  
Additive, synergistic or antagonistic effects  
When comparing with the antioxidant activity and bioactive compounds content of each 
plant per se, the results obtained for the present mixtures and formulations are close to 
those reported for borututu, which is, by far, the plant with most active derived products 
among the three assayed species.13 As a consequence, the possibility of having a 
synergistic effect within the prepared mixtures was raised. This hypothesis was 
mathematically verified by calculating the simple mean (for 1:1:1 mixture), or the 
weighted mean (in all remaining mixtures). The results of these calculations are 
indicated as theoretical values (Table 2); regarding the anti-hepatocellular carcinoma 
activity, the GI50 values higher than 400 µg/mL (the maximum assayed concentration) 
were included as being 400, since this is precisely the value that most hinder the 
possible synergistic effect; i.e., if a given mixture shows synergistic effect when 
considering the GI50 value of a determined plant (or plants) as being 400 µg/mL instead 
of the non-obtained (higher) experimental value, than the effect resulting from including 
the real  experimental value, would certainly be synergistic. With no exception, the 
mixtures of all formulations gave synergistic effects in antioxidant activity. In fact, the 
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highest activity of mixtures when compared to the individual plants was previously 
observed in formulations containing fennel, lemon-verbena and spearmint.22 
Nevertheless, the mixtures 2:1:1 and 1:1:2, for pills and syrups, and also mixture 1:2:1, 
for syrups, did not result in a synergistic effect in what regards the anti-hepatocellular 
carcinoma activity on HepG2. The hepatotoxicity, as evaluated on PLP2 cells, was 
always lower in the mixtures, when compared to the activity of single plants,13,14 which 
represents also a good result considering the previously stated objective of obtaining 
non-toxic mixed formulations.  
 
Linear discriminant analysis of antioxidant properties 
In order to have a complete perspective about the effect of F and R on the antioxidant 
activity and bioactive compounds amounts, two linear discriminant analysis were 
applied (the anti-hepatocellular carcinoma activity and hepatotoxicity results were not 
included, since there were some cases with GI50 > 400 µg/mL that could not be 
included). The significant independent variables (results for antioxidant activity assays 
and bioactive compound contents) were selected following the stepwise method of the 
LDA, according to the Wilks’ λ test. Only variables with a statistically significant 
classification performance (p < 0.05) were kept in the analysis.  
In the case of F effect, 2 significant functions were defined (plotted in Figure 3), which 
included 100.0% of the observed variance (first, 58.2%; second, 41.8%). As it can be 
observed, the tested groups (infusion, pill and syrup) were completely individualized 
(shadowed ellipses). Function 1 was primarily correlated to TBARS formation 
inhibition, DPPH scavenging inhibition and β-carotene bleaching inhibition, which were 
much lower in pill formulation. Actually, this function separated mainly pills from the 
remaining formulations, as confirmed by the means of canonical variance (MCV: 
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infusion, -4.684; pill, 5.212; syrup, -0.529. Function 2, by its side, was more correlated 
to reducing power (lower in syrup), total phenolics and total flavonoids (in higher 
quantities in syrups). Accordingly, as it can be seen in the vertical axis, function 2 
clearly separated syrup formulation (MCV: infusion, -2.806; pill, -2.031; syrup, 4.837). 
All samples were correctly classified, either for original grouped cases, as well as for 
cross-validated grouped cases. 
Regarding A:B:M ratio, the discriminant model selected 3 significant functions (Figure 
4), which included 100.0% of the observed variance (function 1: 65.3%, function 2: 
20.9%, function 3: 13.8%). In this case, the tested groups (1:1:1, 2:1:1, 1:2:1 and 1:1:2) 
were not completely individualized, indicating that the differences determined in the 
antioxidant activity assays and bioactive compounds contents were not enough to 
discriminate the tested groups. The classification performance allowed 65% of correctly 
classified samples (sensitivity) and 64% of overall specificity within the leave-one-out 
cross-validation procedure (Table 3). Despite all variables were kept in the final 
analysis, it became obvious that the differences verified for the assayed ratios were not 
as significant as it would be necessary to obtain individualized groups. This can be 
clearly observed in Figure 4, in which several overlapping markers confirm the 
similarity among the assayed mixtures of artichoke, borututu and milk thistle.  
 
Conclusions  
Overall, the interaction among F and R was significant in all cases, indicating that the 
effects caused by each assayed formulation are related to the used proportion of each 
plant. Even so, syrups tended to be the formulation with highest antioxidant activity and 
the higher contents in total phenolics and flavonoids; this was specially verified when 
the mixture 1:1:2 was used, as it can be concluded from the estimated marginal mean 
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plots. On the other hand, pills were the worst formulation, independently of the used 
mixture. In what concerns artichoke:borututu:milk thistle ratios, the results did not 
reveal so observable differences. The higher influence of F in comparison with R was 
clearly highlighted by the LDA outputs. In addition, the effects of each factor were 
significantly different, since the correlations among discriminant functions and selected 
variables were different within each statistical test. The obtained outputs confirmed the 
significant differences among infusions, pills and syrups, showing also that the 
artichoke:borututu:milk thistle ratios used in the mixtures had much lower effects in the 
antioxidant activity assays and bioactive compounds contents. 
With no exception, the mixtures for all formulations gave synergistic effects for 
antioxidant activity assays, and also in several assays regarding hepatocellular 
carcinoma toxicity, when compared to the activity of single plants. Moreover, none of 
the samples showed toxicity for liver primary cells.   
The obtained results might be helpful to define the best formulation and mixing 
proportions to be used in the preparation of non-toxic products derived from artichoke, 
borututu and milk thistle.  
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Table 1. In vitro antioxidant properties (EC50, mg/mL) and bioactive compounds content for the different formulations prepared from artichoke 
(A), borututu (B) and milk thistle (M). The results are presented the as mean±SDa. 
 
 Total phenolics 
 (mg GAE/g) 
Total flavonoids 
(mg CE/g) 
DPPH scavenging  
activity   
Reducing 
 power 
β-Carotene bleaching 
 inhibition 
TBARS formation  
inhibition 
Formulation (F) 
infusion 148±19 34±4 0.4±0.1 0.2±0.1 0.15±0.03 0.06±0.01 
pill 69±11 5±1 1.2±0.4 0.4±0.1 2±1 0.3±0.1 
syrup 469±164 78±32 0.3±0.2 0.06±0.02 0.10±0.02 0.03±0.01 
p-value (n=36) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
        
A:B:M ratio (R) 
1:1:1 232±178 38±33 0.6±0.2 0.2±0.1 0.3±0.3 0.2±0.2 
2:1:1 172±112 31±20 1.0±0.5 0.3±0.2 1±1 0.1±0.1 
1:2:1 198±121 31±20 0.5±0.4 0.2±0.1 1±1 0.1±0.1 
1:1:2 312±301 55±54 0.6±0.4 0.3±0.2 2±2 0.1±0.1 
p-value (n=27) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
F×R p-value (n=108) <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
EC50- extract concentration corresponding to 50% of antioxidant activity or 0.5 of absorbance for the Ferricyanide/Prussian blue assay (reducing power).  
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Table 2. Theoreticala versus experimental values of antioxidant EC50 (mg/mL) and antiproliferative GI50 (µg/mL) activities of different 
mixtures and formulations. 
Bioactivity 
Theoretical Experimental Effect Theoretical Experimental Effect Theoretical Experimental Effect Theoretical Experimental Effect 
1:1:1 2:1:1 1:2:1 1:1:2 
Infusion 
DPPH scavenging activity 1.56 0.38±0.02 SN 1.72 0.42±0.04 SN 1.22 0.25±0.02 SN 1.80 0.48±0.03 SN 
Reducing power 1.22 0.16±0.01 SN 1.38 0.30±0.02 SN 0.97 0.18±0.01 SN 1.36 0.32±0.02 SN 
β-carotene bleaching inhibition 1.21 0.11±0.01 SN 1.34 0.16±0.01 SN 1.07 0.13±0.01 SN 1.26 0.18±0.01 SN 
TBARS inhibition 0.17 0.06±0.01 SN 0.16 0.06±0.01 SN 0.13 0.04±0.01 SN 0.22 0.07±0.01 SN 
HepG2 (hepatocellular carcinoma) 199.37 24±1 SN 162.55 49±8 SN 186.05 63±7 SN 249.53 67±2 SN 
 Pill 
DPPH scavenging activity 6.46 0.85±0.05 SN 7.43 1.85±0.03 SN 5.22 1.07±0.03 SN 6.94 1.12±0.04 SN 
Reducing power 1.31 0.38±0.02 SN 1.56 0.49±0.02 SN 1.14 0.35±0.03 SN 1.27 0.43±0.02 SN 
β-carotene bleaching inhibition 7.70 0.77±0.04 SN 5.84 2.35±0.05 SN 7.24 1.82±0.05 SN 10.27 4.19±0.05 SN 
TBARS inhibition 0.86 0.43±0.02 SN 1.03 0.29±0.01 SN 0.74 0.17±0.01 SN 0.85 0.25±0.02 SN 
HepG2 (hepatocellular carcinoma) 400 360±14 SN 400 >400 AD 400 340±2 SN 400 >400 AD 
 Syrup 
DPPH scavenging activity 74.89 0.43±0.02 SN 113.05 0.66±0.05 SN 57.07 0.18±0.02 SN 56.81 0.11±0.01 SN 
Reducing power 24.51 0.05±0.01 SN 36.85 0.08±0.01 SN 18.83 0.08±0.01 SN 18.58 0.03±0.01 SN 
β-carotene bleaching inhibition 5.91 0.10±0.01 SN 8.82 0.13±0.01 SN 4.61 0.12±0.01 SN 4.48 0.07±0.01 SN 
TBARS inhibition 7.08 0.03±0.01 SN 10.68 0.04±0.01 SN 5.40 0.04±0.01 SN 5.38 0.02±0.01 SN 
HepG2 (hepatocellular carcinoma) 360.16 317± 12 SN 370.12 >400 AN 370.12 >400 AN 340.24 >400 AN 
aThe theoretical values were obtained considering summative contributions of the individual species. A- Additive effect: theoretical and experimental EC50/GI50 values reveal differences below 
5%. S- Synergistic effect: experimental EC50/GI50 values are more than 5% lower than theoretical values. AN - antagonist effect: experimental EC50 values are more than 5% higher than 
theoretical values. 
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Table 3. Contingency matrix obtained using LDA based on antioxidant activity and bioactive compounds content in different artichoke:borututu: 
milk thistle ratios. 
 
 
Predicted group membership 
Total 
Sensitivity 
(%) 1:1:1 2:1:1 1:2:1 1:1:2 
1:1:1 19 7 1 0 27 70 
2:1:1 9 9 0 9 27 33 
1:2:1 6 0 21 0 27 78 
1:1:2 0 0 6 21 27 78 
Total 34 16 28 30 108 65 
Specificity (%) 56 56 75 70 64  
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Figure 1. Interactions between formulation (F) and artichoke:borututu:milk thistle ratio (R) 
effects on bioactive compounds content. Total phenolics (A), total flavonoids (B). 
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Figure 2. Interactions between formulation (F) and artichoke:borututu:milk thistle ratio 
(R) on the antioxidant activity. DPPH scavenging activity (A), reducing power assay (B), 
β-carotene bleaching inhibition (C), TBARS formation inhibition (D). 
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Figure 3. Discriminant scores scatter plot of the canonical functions defined for 
bioactive compounds content and antioxidant activity results according with 
formulation. 
 
 
 
 
 
 24 
 
 
 
Figure 4. Discriminant scores scatter plot of the canonical functions defined for 
bioactive compounds content and antioxidant activity results according with 
artichoke:borututu:milk thistle ratio. 
  
 
